Over the past quarter, Ichnos has completed the steps required to form an independent
company, including the transition of colleagues in the United States and Switzerland to
Ichnos Sciences. Due to difficulties encountered in obtaining approval from the authorities
in India, Glenmark employees who were previously expected to transfer to Ichnos will
remain with Glenmark. These individuals will continue to do work for Ichnos on NCE for
the treatment of cancer through an agreement between the two companies.
To read more, download the full update PDF.